IBJNews

Lilly, Amylin stock rises on drug postponement

Back to TopCommentsE-mailPrintBookmark and Share

Roche Holding AG’s decision to postpone its experimental diabetes drug taspoglutide is turning out to be a boon for Amylin Pharmaceuticals Inc. and drug partner Eli Lilly and Co., whose twice-weekly injection would compete with Roche’s once-weekly shot.

Amylin stock rose the most in 14 months in Friday morning trading after the Byetta competitor was delayed over side effects. Shares rose $2.57, or 16 percent, to $19.09 each as of late morning.

Lilly shares rose 34 cents, to $34.73 each, Friday morning, while Roche stock declined 2.2 percent.

Roche postponed the drug by at least 12 to 18 months after more people than expected had side effects, including skin reactions and digestive complications. Some patients also experienced heart and respiratory problems, though everyone recovered, the Basel, Switzerland-based company said Friday in an e-mail.
Roche had planned to ask regulators to approve the diabetes drug, which it licensed from Ipsen SA in 2006, next year.

Byetta is Amylin’s top-selling product with $668 million in sales last year, or 88 percent of total revenue.

Lilly received $449 million from Byetta sales in 2009, up 13 percent from 2008.

“This morning’s news is clearly a positive for Amylin, as it further hobbles taspoglutide, if not removes it from the competitive landscape entirely,” said Philip Nadeau, an analyst at Cowen & Co. in New York, in a report to clients. “There would seem to be a good chance that taspoglutide does not make it to market.”

Roche said it needs additional time to identify the people more likely to be sensitive to the medicine and to remove them from clinical trials.

The delay is a setback for Roche’s efforts to expand outside of cancer drugs, which account for the company’s three best-selling products and about 50 percent of pharmaceutical sales. The injection would compete with Byetta as well as Novo Nordisk A/S’s Victoza.

“A delay of 12 to 18 months is not good,” Andrew Weiss, an analyst at Bank Vontobel AG in Zurich, said. “It’s an important drug for Roche and they need it on the market to balance out the oncology franchise, which is starting to slow down.”

Roche is seeking to determine which patients are most at risk through a test to identify anti-drug antibodies, which are the body’s immune response to a medicine and can result in allergic reactions. The company said it will remove patients whose levels of antibodies exceed a certain level. The incidence of the response, which is common in protein-based medicines, is less than 1 percent with taspoglutide, Roche said.

“Given the fact that the hypersensitivity is a low event rate, it’s OK, but anti-drug antibodies are something to be taken seriously,” Weiss said.

Lilly and Amylin have asked the U.S. Food and Drug Administration to approve a once-a-week version of Byetta called Bydureon. The FDA asked March 15 for clarification of manufacturing processes, labeling and a risk-management plan. Antibodies are also a concern for Bydureon, Weiss said.

Roche wants to expand beyond its best-selling cancer drugs and take a share of the $24 billion-a-year diabetes market. The number of people with the condition is expected to rise to 366 million by 2030, according to the World Health Organization.

Taspoglutide is a GLP-1 analogue, a newer class of diabetes medicine that boosts insulin production after meals. The Roche medicine helped lower blood sugar levels and promote weight loss in late-stage studies of patients with type-2 diabetes.
 

ADVERTISEMENT

  • Lilly Zyprexa diabetes conflict
    Eli Lilly promotes sales of their #1 drug (Zyprexa $4.8 billion per year) that can *cause* diabetes and then turns around and makes billions selling more drugs to treat the diabetes.
    Lilly's cash cow Zyprexa has been over-prescribed and linked to a 10-times greater risk of causing type 2 diabetes and increased risk of heart attack.
    At 5 to ten times the cost of the old standby thorazine,recent comparative studies show the diabetes inducing zyprexa class of drugs are only borderline better in controlling symptoms.
    Only 9 percent of adult Americans think the pharmaceutical industry can be trusted right around the same rating as big tobacco. No Wonder!
    Daniel Haszard Zyprexa whistle-blower

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. I think the poster was being sarcastic and only posting or making fun of what is usually posted on here about anything being built in BR or d'town for that matter.

  2. Great news IRL fans: TURBO the IMS sanctioned movie about slugs running the Indy 500 has caught the Securities and Exchange Commission because Dreamworks had to take a $132MILLION write down...because the movie was such a flop. See, the Indy/IMS magic soiled another pair of drawers. Bwahahahahahaha! How's CARTOWN doing? HAHAHAHA...Indy is for losers.

  3. So disappointed in WIBC. This is the last straw to lose a good local morning program. I used to be able to rely on WIBC to give me good local information, news, weather and traffic on my 45 minute commute.Two incidents when I needed local, accurate information regarding severe weather were the first signs I could not now rely on WIBC. I work weekend 12 hour nights for a downtown hospital. This past winter when we had the worst snowfall in my 50 years of life, I came home on a Sunday morning, went to sleep (because I was to go back in Sunday night for another 12 hour shift), and woke up around 1 p.m. to a house with no electricity. I keep an old battery powered radio around and turned on WIBC to see what was going on with the winter storm and the roads and the power outage. Sigh. Only policital stuff. Not even a break in to update on the winter storm warning. The second weather incident occurred when I was driving home during a severe thunderstorm a few months ago. I had already gotten a call from my husband that a tornado warning was just southwest of where I had been. I turned to WIBC to find out what direction the storm was headed so I could figure out a route home, only to find Rush on the air, and again, no breaking away from this stupidity to give me information. Thank God for my phone, which gave me the warning that I was driving in an area where a tornado was seen. Thanks for nothing WIBC. Good luck to you, Steve! We need more of you and not the politics of hatred that WIBC wants to shove at us. Good thing I have Satellite radio.

  4. I read the retail roundup article and tried Burritos and Beers tonight. I'm glad I did, for the food was great. Fresh authentic Mexican food. Great seasoning on the carne asada. A must try!!! Thanks for sharing.

  5. John, unfortunately CTRWD wants to put the tank(s) right next to a nature preserve and at the southern entrance to Carmel off of Keystone. Not exactly the kind of message you want to send to residents and visitors (come see our tanks as you enter our city and we build stuff in nature preserves...

ADVERTISEMENT